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Purpose: Epoprostenol, used for the treatment of pulmonary arterial hypertension (PAH), has 
a number of limitations related to its short half-life in aqueous solution. The aim of this study 
was to evaluate the stability and microbiological properties of a new formulation, namely epo-
prostenol sodium with arginine and mannitol excipients (epoprostenol AM; Veletri®; Actelion 
Pharmaceuticals Ltd, Allschwil, Switzerland).
Methods: Stability and microbiological properties of epoprostenol AM were investigated at 
5°C, 25°C, and 30°C over a range of concentrations (3000–30,000 ng/mL) when reconstituted 
and immediately diluted with sterile water for injection (SWI) or sterile saline (sodium chloride 
0.9%) for injection (SSI). Stability (change in potency over time) for up to 72 hours at 25°C 
and 30°C was measured immediately following dilution and after storage at 5°C. Shelf-life was 
assessed by determining the maintenance of potency over time relative to initial potency. For 
microbiological testing, diluted samples of epoprostenol AM were inoculated with a range of 
bacteria, yeasts, and molds for up to 14 days at 5°C or 4 days at 25°C.
Results: Epoprostenol AM reconstituted and immediately diluted to the required concentration 
with SWI or SSI was stable for up to 3 days at 25°C and up to 7 days at 5°C depending on the 
concentration. None of the diluted epoprostenol AM solutions supported microbial growth for 
any of the six organisms tested for up to 14 days.
Conclusions: Epoprostenol AM has improved thermal stability and does not support the 
growth of any microorganism tested for up to 14 days. This extended stability under ambient 
conditions has the potential to improve convenience for patients.
Keywords: stability, epoprostenol, formulation, microbial activity, diluents, pulmonary arterial 
hypertension
Introduction
Prostacyclin (prostaglandin I2) is an important vasoactive and homeostatic mediator 
produced from arachidonic acid in the cell membrane of vascular endothelial cells 
by the action of cyclooxygenase. Prostacyclin is a potent vasodilator and possesses 
antithrombotic, antiproliferative and anti-inflammatory properties. These proper-
ties have led to the use of prostacyclin, in the form of the sodium salt of the synthetic 
exocyclic vinyl ether epoprostenol, as a treatment for pulmonary arterial hyperten-
sion (PAH), a devastating disease characterized by vasoconstriction, in situ throm-
bosis and remodeling of the pulmonary vessel wall.1 However, similar to naturally 
occurring prostacyclin, epoprostenol hydrolyzes rapidly to 6-keto-prostaglandin F1α   
(6-keto-PGF1α) in a pH-dependent fashion in aqueous solutions, and the in vivo 
half-life of epoprostenol in humans is thought to be less than 6 minutes.2 This hydrolytic 
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lability makes the development of a robust formulation of 
epoprostenol for clinical use challenging.
Commercially available epoprostenol with glycine 
and mannitol excipients (epoprostenol GM; Flolan®; 
  GlaxoSmithKline, Durham, NC) was approved by the US Food 
and Drug Administration (FDA) in 1995 but was first used 
to treat primary pulmonary hypertension in the early 1980s.3 
Since then a number of randomized, controlled, open-label 
trials of the intravenously administered drug have shown a ben-
eficial effect on exercise capacity, hemodynamics and quality 
of life, as well as improvements in survival, in patients with 
PAH.4–8 Based on these data, epoprostenol is recommended for 
the treatment of patients with moderate-to-severe PAH (World 
Health Organization functional groups III/IV).9,10
Epoprostenol GM is supplied in lyophilized vials which 
contain either 0.5 mg or 1.5 mg epoprostenol sodium and 
which must be reconstituted and diluted immediately before 
use using only the proprietary diluent. In solution, epopros-
tenol GM has limited stability at room temperature (maxi-
mum recommended: 24 hours at 2°C–8°C, or 8 to 12 hours 
at 25°C),11 which necessitates refrigerated storage. Due to the 
short plasma half-life of epoprostenol, epoprostenol GM must 
be administered by continuous venous infusion via a central 
venous catheter for the duration of therapy. The limited sta-
bility of epoprostenol GM means that frequent changes of 
reservoir cartridge (#8 hours) are required for administration 
at room temperature or, for administration over a 24-hour 
period, frozen gel packs which must be changed regularly 
throughout the day are necessary to ensure the solution is kept 
at 2°C–8°C. The need to use only the specific epoprostenol 
GM diluent for reconstitution, and the need for refrigeration 
or the use of frozen gel packs during long-term administra-
tion, leads to considerable inconvenience for the patient. In 
addition, abrupt interruptions of epoprostenol infusion must 
be avoided as, in some patients, this may lead to rebound 
PAH with symptomatic deterioration and may even result in 
death.10 Continuity of supply is therefore critical. A formula-
tion of epoprostenol with a better stability profile, particularly 
under ambient conditions, the ability to be reconstituted with 
commercially available intravenous diluents rather than a 
specific commercial diluent to improve ease of use, and the 
ability to be infused under ambient conditions, rather than 
requiring ice packs for prolonged delivery, would therefore 
clearly represent an improvement in convenience and, poten-
tially, in safety.
A new product, namely epoprostenol sodium with arginine 
and mannitol excipients (epoprostenol AM; Veletri®; Actelion 
Pharmaceuticals Ltd, Allschwil, Switzerland), has been 
developed which is very stable and which can be reconstituted 
using commercially available infusion diluents. Epoprostenol 
AM reconstituted in the vial with 5 mL of either sterile water 
for injection (SWI) or sterile saline (sodium chloride 0.9%) 
for injection (SSI) may be refrigerated at 2°C–8°C for as 
long as 5 days or held at up to 25°C for up to 48 hours prior 
to final dilution for use.12 The aims of the current study were 
to investigate the stability and microbiological properties 
of epoprostenol AM, immediately fully diluted following 
reconstitution, at 5°C and 25°C over a range of concentrations 
to determine the handling shelf-life when stored at the final, 
ready-to-use dilution. The hemolytic properties of diluted 
epoprostenol AM under clinical conditions were also assessed 
to ensure that the relatively high pH of the formulation did not 
have an adverse effect on blood.
Methods
Formulation
Epoprostenol AM is formulated as a sterile, lyophilized   powder. 
In addition to epoprostenol 1.5 mg/vial as the sodium salt, the 
new formulation contains L-arginine US   Pharmacopoeia 
National Formulary (USP/NF) at 50 mg/vial (buffering agent), 
mannitol USP/European Pharmacopoeia (EP)/Japanese 
Pharmacopoeia (JP) at 50 mg/vial (bulking agent), and sodium 
hydroxide USP/NF/EP/JP for pH adjustment.
Microbiological testing
Cultures of Staphylococcus aureus, Pseudomonas aeruginosa, 
Escherichia coli, Candida albicans, Aspergillus niger, and 
Clostridium sporogenes (Remel Quanti-Cult Plus; Thermo 
Fisher Scientific, Lenexa, KS) were prepared as per manufac-
turer’s instructions and used within 24 hours of preparation. 
An initial plate count using each microbial suspension was 
performed to confirm appropriate level of microorganism 
(,10 colony-forming units [CFU]/mL) as follows: each 
microbial suspension was plated into sterile Petri dishes in 
duplicate. Using the pour plate method, bacteria were plated 
with tempered microbial content test agar (MCTA) and yeast 
and molds with tempered Sabouraud Dextrose Agar (SDA+). 
Plates were incubated for 3–5 days at 30°C–35°C for bacte-
ria and 20°C–25°C for yeast and molds (C. sporogenes was 
incubated under anaerobic conditions).
Epoprostenol AM was diluted to provide 3000, 6000, 9000, 
15,000, or 30,000 ng/mL samples, using either SWI or SSI, 
and stored in sterile glass containers. Each sterile sample of 
diluted epoprostenol AM was inoculated with ,10 CFU/mL 
of each microbial suspension to simulate potential use condi-
tions. Contents were mixed to   homogenize samples. Samples 
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were stored for incubation for up to 96 hours at 25°C   
(all dilutions), or for up to 14 days at 5°C (9000 and 30,000 ng/
mL) followed by 24 hours at 25°C before plating, incuba-
tion and counting. Each container was sampled at the given 
intervals and the number of CFU counted by using the same 
procedure as described above for the initial plate count. Analy-
ses were performed in duplicate. The CFU were counted and 
the log10 reduction calculated. To allow for assay variability, 
“no increase” was defined as no increase in CFU . 0.5 log10 
relative to the initial inoculum.
The test period used was chosen to reflect the stability of 
the product and likely clinical usage. Testing was performed at 
twice the expected period of stability. The period of incubation 
at 25°C was longer for higher concentration solutions ($15,000) 
than for lower concentration solutions (#6000 ng/mL) reflect-
ing the lower chemical stability (and therefore shorter storage 
times) of low concentration solutions.
Chemical stability studies
Epoprostenol AM was reconstituted with 5 mL of either 
SWI or SSI. Reconstituted solutions were then immediately 
diluted to the final concentration (3000, 6000, 9000, 12,000 
or 30,000 ng/mL) with the same diluents and stored in 50 mL 
CADDTM medication cassette reservoirs (polyvinyl chloride 
reservoir) (Smiths Medical MD Inc, St Paul, MN). Stability 
was measured in the medication cassette at 25°C under the 
following test conditions: (A) immediately following dilution 
at time points up to 72 hours at 25°C and 30°C, depending 
on concentration; (B) following 1 day storage at 5°C, and 
then up to 24 hours at 25°C, for 6000 ng/mL only; (C) fol-
lowing 7 days’ storage at 5°C, and then up to 24 hours at 
25°C, depending on concentration (Table 1). Testing varied 
for different dilutions in that some tests were not performed 
for particular dilutions where that dilution was known to be 
unstable under the conditions indicated.
Incubations were performed in dark temperature and 
humidity-controlled test chambers. Samples were also 
protected from outside humidity and light by virtue of the 
medication cassette. The potency over time was determined 
relative to initial potency for all conditions of storage, and 
used to determine shelf-life of diluted epoprostenol AM.
For epoprostenol AM 6000 ng/mL and 12,000 ng/mL, 
shelf-life after storage at 5°C was calculated by combining 
data collected after storage at 5°C and data collected after 
storage at 25°C as follows:
Assay(x days @ 5°C + y days @ 25°C) =
 Assayx days @ 5°C × Assayy days @ 25°C
  100
Potency was determined using a high-performance liquid 
chromatography (HPLC) method. Epoprostenol is a challeng-
ing analyte due to the rapid hydrolysis in aqueous solutions 
and also due to the weak chromophor which necessitates a 
very low detection wavelength. HPLC was performed using 
a Phenomenex Gemini C18, 5 µm, 110 Å, 250 × 4.6 mm 
column (Phenomenex, Torrance, CA) where the conditions 
were as follows: autosampler temperature 5°C ± 3°C; column 
temperature 25°C ± 3°C; flow rate 1.0 mL/min; mobile phase 
A 80% 25 mM pH 9.0 borate buffer/20% acetonitrile (v/v) 
and B 50% water/50% acetonitrile (v/v), gradient–time 0 
100% A/0% B, time 15.01 minutes and 25.01 minutes 0% 
A/100% B, time 30 minutes 100% A/0% B; injection volume 
20 µL; retention time of epoprostenol peak was approximately 
10 minutes; chromatographic run time 30 min; detection 
wavelength: 205 nm. Reference standard was   epoprostenol 
Table 1 Stability protocola
Concentration Time interval/storage conditions
Condition A Condition B Condition C
3000 ng/mL 0, 8, 12, 24 hours at 25°C 
0, 8, 12, 24 hours at 30°C
nd nd
6000 ng/mL 0, 8, 12, 24 hours at 25°C 
0, 8, 12, 24 hours at 30°C
0, 24 hours at 5°C plus  
0, 12 hours at 25°C
nd
9000 ng/mL 0, 24 hours at 25°C 
0, 24 hours at 30°C
nd 0, 7 days at 5°C plus 
12 hours at 25°C
12,000 ng/mL 0, 24, 48, 72 hours at 25°C 
0, 24, 48, 72 hours at 30°C
nd nd
30,000 ng/mL 0, 24, 48, 72 hours at 25°C 
0, 24, 48, 72 hours at 30°C
nd 0, 7 days at 5°C plus 
24 hours at 25°C
Notes: aConditions tested varied by dilution based on the known stability of diluted epoprostenol AM; condition A: tested immediately following dilution at time points up 
to 72 hours at 25°C and 30°C, depending on concentration; condition B: tested following 1 day storage at 5°C and then up to 24 hours at 25°C, for 6000 ng/mL; condition C: 
tested following 7 days’ storage at 5°C and then up to 24 hours at 25°C, depending on concentration. 
Abbreviations: AM, arginine and mannitol; nd, not done.
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as the sodium salt (SAI Advantium Pharma Ltd, Hyderabad, 
India). The method has been validated with respect to 
specificity, range (accuracy, linearity, precision) for both 
epoprostenol and related substances, limit of detection, limit 
of quantitation, relative response factor for 6-keto-PGF1α, 
robustness and solution stability.
Levels of related substances were also determined. 
Unidentified peaks were only designated as “true” degrada-
tion products if they occurred at consecutive time points or 
at the last time point of the respective study. Due to the low 
detection wavelength, minute impurities originating, for 
instance, from dissolved air or the eluent giving rise to such 
spurious peaks are easily detected. Shelf-life was assessed by 
determining the period of time over which a potency greater 
than or equal to 90% of the initial value measured follow-
ing dilution and prior to storage (time 0) was maintained. 
However, slightly lower potency was also considered accept-
able, particularly for solutions with low epoprostenol AM 
concentrations for two reasons: (1) upon validation standard 
deviation of the method was found to be higher relative to the 
higher concentrations, probably due to the greater number 
of dilution steps and (2) in clinical practice low concentra-
tion solutions are used during the treatment initiation phase, 
where a patient’s response to the drug is closely monitored 
in a hospital setting and the dose can be adjusted if needed. 
For these reasons, a remaining potency of $86% compared 
with initial potency was considered to be an acceptable level 
without compromising patient safety.
The pH of diluted solutions, taken at each study point was 
conducted using a PerpHect Ross Sure-Flow Combination 
pH electrode (Thermo Scientific, Barrington, IL). Changes 
in physical appearance or particulate matter were examined 
by observing the samples in clear glass containers against a 
black background by eye.
Assessment of hemolytic properties
Whole human blood from an adult volunteer was collected 
into standard vials containing sodium heparin anticoagulant 
and used for testing on the same day. A 1.5 mg vial of 
epoprostenol AM was reconstituted and diluted to give a 
final concentration of 15,000 ng/mL using SSI and SWI. 
A 70 µL aliquot of each solution was added to 5 mL of 
blood. This ratio was selected based on estimates of the infu-
sion rate of the diluted product and peripheral blood flow 
in the forearm. The infusion rate of the diluted product was 
estimated to be ∼0.05 mL (50 µL) per pulse of the pump; 
therefore, a slightly higher value (70 µL) was selected as 
the worst case scenario. The blood flow rate in the forearm 
has been calculated to be 3–30 mL/minute.13 At the high-
est   dosing rate, one pulse is delivered every 30 seconds; 
therefore, at the slowest blood flow, 50 µL of diluted product 
would contact ∼1.5 mL of blood. However, as epoprostenol 
AM is generally administered via a central venous catheter, 
the volumetric blood flow rate would be much higher, and 
so dilution of the product will be greater. Nevertheless, the 
final dilution tested was estimated as a worse case volume 
to simulate delivery into a peripheral vein, as temporary 
peripheral infusion may be used until central access is estab-
lished. Samples were incubated at 37°C in a water bath, and 
then centrifuged for 10 minutes at 3000 rpm (2095 × g) at 
ambient temperature. All preparations were made in trip-
licate. For comparison, samples containing glycine buffer 
diluents (Flolan® diluent; GlaxoSmithKline), 60 µg/mL 
sodium hydroxide in normal saline, and pH 13-adjusted 
normal saline were prepared in the same way. Samples of 
whole blood only were used to monitor the hemolytic impact 
of the procedure.
Two methods were used to estimate the hemolysis. In the 
first, the values were compared to a hemoglobin standard. 
A standard curve for hemoglobin concentration was created 
as per the ASTM Protocol F756.14 Samples were treated 
with cyanmethemoglobin (CMH) reagent for spectroscopic 
measurement (absorbance 540 nm; Hewlett Packard 8435 
UV-Visible spectrophotometer with 1 cm quartz cuvette) to 
reduce all the forms of hemoglobin. Percent hemolysis was 
calculated by conversion of spectrophotometric absorbance 
to hemoglobin values using the standard curve and dividing 
by the total blood hemoglobin level for the blood sample 
used. In the second method, the hemolysis in the samples 
was compared to controls of 1:1 blood:normal saline (0% 
hemolysis) and 1:1 blood:deionized water (100% hemolysis) 
using a procedure adapted from the literature.13–15   Absorbance 
was measured at 540 nm and % hemolysis calculated by 
dividing the sample absorbance value by the absorbance 
value representing 100% hemolysis.
Results
Microbiological findings
No increase, but a real reduction, with respect to initial 
inoculum of any tested organism was seen in any diluted 
sample (ranging from 3000 to 30,000 ng/mL) of epopros-
tenol AM in either diluents over the full course of the study 
(48–96 hours depending on dilution at 25°C; 14 days at 5°C) 
(Tables 2 and 3). A few results for A. niger and C. albicans 
appeared to be static with all below the level defined as 
growth (0.5 log10).
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Potency of diluted epoprostenol AM 
over time
The potency of epoprostenol AM 3000 ng/mL–30,000 ng/mL 
during storage at 25°C and 30°C following immediate dilu-
tion (test condition A) is shown in Table 4 and Table 5, 
respectively.
At 25°C, potency of epoprostenol AM was .90% up 
to 24 hours at concentrations between 9000 ng/mL and 
12,000 ng/mL, and 72 hours at 30,000 ng/mL. Acceptable 
levels of potency ($86%) were seen up to 12 hours at 25°C 
for epoprostenol AM 3000 ng/mL and 24 hours for epopros-
tenol AM 6000 ng/mL. Loss of potency was higher at 30°C 
compared with 25°C for all dilutions tested. Additional loss 
in potency did not exceed 0.2% per hour at 30,000 ng/mL, 
0.3% at 12,000 and 9000 ng/mL, 0.5% at 6000 ng/mL, and 
1% at 3000 ng/mL. No relevant increase in the level of any 
unknown impurity was observed under any condition tested. 
No change in physical appearance or any visible particulate 
matter was observed.
Potency of diluted epoprostenol AM 
following storage at 5°C
Test conditions and potency of epoprostenol AM following 
storage at 5°C following immediate dilution is shown in 
Table 6. Potency data after 1 day storage at 5°C were unavail-
able for epoprostenol AM 12,000 ng/mL; therefore, the data 
obtained with epoprostenol AM 6000 ng/mL were used to 
calculate final potency under test condition B. Since stability 
was shown to be lower at lower concentrations, this therefore 
represents a “worst case” scenario. Based on this, potency of 
epoprostenol AM 12,000 ng/mL under test condition B (1 day 
at 5°C plus 12 hours at 25°C) was calculated to be $90% 
for both diluents. No data were available for test condition C 
Table 4 Potency of epoprostenol AM 3000–30,000 ng/mL stored 
at 25°C following immediate dilution
Epoprostenol  
AM, ng/mL
Diluent Potency over time (hours), %
0 8 12 24 72
3000 SWI 100 92 88 75 nd
SSI 100 91 86 72 nd
6000 SWI 100 96 93 87 nd
SSI 100 94 93 86 nd
9000 SWI 100 nd nd 90 nd
SSI 100 nd nd 90 nd
12,000 SWI 100 nd nd 91 nd
SSI 100 nd nd 93 nd
30,000 SWI 100 nd nd 97 91
SSI 100 nd nd 97 90
Abbreviations: AM, arginine and mannitol; SWI, sterile water for injection; SSI, 
sterile saline (sodium chloride 0.9%) for injection; nd, not done.
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No change in physical appearance or any visible particulate 
matter was observed.
pH of diluted solutions
Overall (at 5°C or 25°C), pH of the diluted solutions ranged 
from 9.9–11.3, with the lowest pH in the 3000 ng/mL solution 
and the highest in the 30,000 ng/mL solution. Variation in pH 
of the diluted solutions was minimal during storage and did 
not show any temporal pattern. pH ranges were as follows: 
3000 ng/mL 9.9–10.4 (SWI) and 9.9–10.2 (SSI); 6000 ng/mL 
10.2–10.4 (both diluents); 30,000 ng/mL 11.0–11.3 (SWI) 
and 10.7–11.2 (SSI) .
Assessment of hemolytic properties
Using the method 1 (the CMH procedure), minimal hemo-
lysis was noted for epoprostenol AM reconstituted in SWI 
(0.2%) and no measurable hemolysis was observed for 
epoprostenol AM reconstituted in SSI. Similarly, using the 
second (normal saline procedure), epoprostenol AM hemoly-
sis of epoprostenol AM reconstituted in SWI was 0.1%, and 
no measurable hemolysis was observed for epoprostenol AM 
reconstituted in SSI. Hemolysis was #0.3% for comparator 
samples. The blood only (no added test materials) produced 
very similar results (Table 7).
Discussion
Due to its limited stability, epoprostenol GM must be 
reconstituted and diluted immediately prior to clinical use, 
with the need for frequent changes of reservoir cartridge 
if administered at room temperature, or the use of frozen 
gel packs which must be changed regularly throughout   
Table 5 Potency of epoprostenol AM 3000–30,000 ng/mL stored 
at 30°C following immediate dilution
Epoprostenol AM, 
ng/mL
Diluent Potency over time (hours), %
0 8 12 24 72
3000 SWI 100 86 79 58 nd
SSI 100 84 76 55 nd
6000 SWI 100 92 88 77 nd
SSI 100 92 88 76 nd
9000 SWI 100 nd nd 83 nd
SSI 100 nd nd 82 nd
12,000 SWI 100 nd nd 86 nd
SSI 100 nd nd 87 nd
30,000 SWI 100 nd nd 93 81
SSI 100 nd nd 92 79
Abbreviations: AM, arginine and mannitol; SWI, sterile water for injection; SSI, saline 
(sodium chloride 0.9%) for injection; nd, not done.
Table 6 Potency of epoprostenol AM 6000–30,000 ng/mL after 
storage at 5°C following immediate dilution
Concentration of 
diluted solution
Diluent Storage conditions Potency, %
6000 ng/mL SWI 24 hours at 5°C 
12 hours at 25°C
92
SSI 24 hours at 5°C 
12 hours at 25°C
92
9000 ng/mL SWI 7 days at 5°C 
12 hours at 25°C
91
SSI 7 days at 5°C 
12 hours at 25°C
87
12,000 ng/mL SWI 24 hours at 5°C 
24 hours at 25°C
91a
SSI 24 hours at 5°C 
24 hours at 25°C
92a
30,000 ng/mL SWI 7 days at 5°C 
24 hours at 25°C
93
SSI 7 days at 5°C 
24 hours at 25°C
90
Notes: aExtrapolated data. Potency was extrapolated using data from 6,000 ng/mL. 
Abbreviations: AM, arginine and mannitol; SWI, sterile water for injection; SSI, sterile 
saline (sodium chloride 0.9%) for injection.
Table 7 Relative hemolysis of epoprostenol formulations
Diluent Hemolysis (%) 
CMH procedure
Hemolysis (%) 
Normal saline   
procedure
Epoprostenol AM  
reconstituted in SWI
0.2 0.1
Epoprostenol AM  
reconstituted in SSI
0.0 0.0
Flolan diluent  
(placebo)
0.1 0.0
Normal saline  
adjusted with 60 µg  
NaOH/100 mL saline
0.0 0.0
Normal saline  
adjusted to pH 13
0.3 0.1
Plain blood (control) 0.0 0.0
Abbreviations: AM, arginine and mannitol; SWI, sterile water for injection; SSI, 
sterile saline (sodium chloride 0.9%) for injection; NaOH, sodium hydroxide; CMH, 
cyanmethemoglobin.
(7 days at 5°C plus 12 hours at 25°C) for epoprostenol AM 
12,000 ng/mL; therefore, the same recommendation made 
for epoprostenol AM 9000 ng/mL was applied to calculate 
shelf-life (worst case scenario). Potency of epoprostenol AM 
30,000 ng/mL under test condition C (7 days at 5°C plus 
24 hours at 25°C) was $90% for both diluents. Furthermore, 
data show that epoprostenol AM 30,000 ng/mL when held 
at 25°C demonstrates stability for up to 72 hours; therefore, 
since storage at 25°C is the worst case scenario compared 
with storage at 5°C, the potency should still be acceptable at 
this dilution for up to 48 hours at 25°C after storage for 1 day 
(24 hours) at 5°C. No relevant increase in the level of any 
unknown impurity was observed under any condition tested. 
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the day to ensure the solution is kept at 2°C–8°C.11   
In addition,   epoprostenol GM must be reconstituted using 
a specific commercial diluent only, adding to the inconve-
nience of treatment.11 In the current study, epoprostenol AM 
fully diluted in either SWI or SSI (3000 to 30,000 ng/mL) 
demonstrated stability of potency for between 12 and 
72 hours at 25°C, depending on concentration, and up to 
24 or 48 hours, depending on concentration, after storage at 
5°C for 1 or 7 days,   respectively. Furthermore, epoprostenol 
AM fully diluted in SWI or SSI was self-preserving, with no 
increase in inoculated microorganisms when held at 25°C for 
up to 48 hours, or at 5°C for up to 14 days, well beyond the 
recommended shelf-lives for the diluted product. This self-
preservation is likely to result from the high pH of the amino 
acid buffer used in epoprostenol AM (10.0–12.5 depending 
on dilution). Testing included a range of microorganisms 
representing a broad spectrum of potential manufacturing, 
nosocomial and household contaminants, including Gram-
negative and Gram-positive bacteria, common fungi, and 
molds. Micrococcus was not included in the present study; 
however, given that it is an important pathogen associated 
with bloodstream infections in patients receiving epopros-
tenol,16 it will be included in future testing.
In the current study, epoprostenol AM showed a high 
degree of stability at 25°C, which varied depending on 
concentration and conditions of use, but was not markedly 
affected by diluents used. Stability, and so shelf-life, is 
generally assessed by determining the period of time over 
which a potency greater than or equal to 90% is maintained; 
however, slightly lower potency was considered accept-
able, specifically for solutions with low epoprostenol AM 
concentrations where the relative standard deviation of 
the method is highest. In addition, low concentrations of 
epoprostenol are used during the treatment initiation phase, 
where patients’ response to the drug is closely monitored in 
a hospital setting and the dose is adjusted if needed. For these 
reasons, a remaining potency of $86% was considered to 
be an acceptable level without compromising patient safety. 
Overall, higher concentrations of epoprostenol AM showed 
greater stability under all test conditions, given that these 
higher concentrations present the higher pH.
Based on the findings of this study, fully diluted epo-
prostenol AM would be acceptable for use at 25°C for up 
to 24 hours at concentrations between 6000 ng/mL and less 
than 30 000 ng/mL, and for up to 72 hours at concentra-
tions of 30,000 ng/mL and above this. Following previous 
storage for 1 day at 5°C, 6000 ng/mL epoprostenol AM 
maintained acceptable activity for up to 12 hours at 25°C. 
Following   previous storage for 7 days at 5°C, epoprostenol 
AM maintained acceptable activity for up to 24 hours at 
25°C depending on dilution. Although potency decreased 
at a greater rate in solutions stored at 30°C, it is considered 
that short excursions at this temperature should not have a 
significant impact on the overall loss of potency, particularly 
at concentrations above 6000 ng/mL, where the additional 
loss of potency at 30°C relative to 25°C did not exceed 0.5% 
per hour. In all solutions tested and under all conditions, no 
relevant increases in related substances or impurities were 
seen. The major hydrolytic metabolite of epoprostenol, 
6-keto-PGF1α, was present but this is not considered relevant 
as it is also a metabolite of endogenous prostacyclin and 
substantially less active than the parent molecule.
The high pH of the reconstituted solution is likely to 
be a major contributor to this improved stability. The vinyl 
ether moiety of epoprostenol is best stabilized in solution 
formulations by buffering under basic conditions (.pH 8.8), 
and high pH solutions (.pH 10) have been used to stabilize 
prostacyclin, for example, to enable extraction from whole 
blood.17 The increasing stability of prostacyclin with increas-
ing pH may be related to the reduced levels of hydronium 
ions in more alkaline solutions, as the hydrolysis of epopros-
tenol is hydronium ion-catalyzed.18 The pH of reconstituted 
epoprostenol AM is around 12.5, and ranged from around 
9.9–11.3 when diluted depending on concentration, with a 
lower pH at lower concentrations. This compares with a range 
of 10.2–10.8 for epoprostenol GM. The narrower range of pH 
seen with epoprostenol GM is due to the use of the proprietary 
buffered diluent compared with the use of nonpropriety SWI/
SSI for epoprostenol AM, which will result in wider variation 
in pH range. The higher pH of reconstituted epoprostenol 
AM reflects the chemical structure of the two amino acids 
used as buffers, arginine in epoprostenol AM and glycine 
in epoprostenol GM. The guanidine group of arginine has a 
particularly high pKa (13.2), whereas the highest pKa value 
for the α-amino group of glycine is 9.8. Therefore arginine 
is surprisingly more suitable for providing a high alkaline 
environment and a better pH control upon dilution in IV 
diluents. The rapid hydrolysis of epoprostenol is catalyzed 
by specific hydronium ions. The observed rate constant can 
be represented by the equation:
kobs = kH
3
O+[H3O+] + kOH-[OH-]
where kobs is overall pseudo-first order rate constant, and kH3O+ 
and kOH- are rate constants for specific hydronium ion and 
hydroxide ion, respectively. As pH increases, the   contribution 
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of the specific hydronium ion catalysis diminishes and hence 
stability is improved.
Several agents with high pH formulations are approved 
for intravenous use, although such formulations may 
potentially have biocompatibility issues. However, epo-
prostenol AM does not exhibit these issues because it is 
administered slowly via a central catheter and in extremely 
small quantities. Thus, there is considerable dilution in the 
blood, and so a reduced potential from problems such as 
hemolysis. Moreover, the concentration of the basic amino 
acid is at a level to maintain the pH, but is also low enough 
to ensure the buffer capacity of the blood is sufficient to 
overcome the pH of the slowly delivered medication. In 
fact, this study showed no difference in hemolysis between 
epoprostenol AM diluted with either SWI or SSI at con-
centrations and dilutions chosen to reflect clinical dose and 
normal blood flow. In addition, the low degree of hemo-
lysis seen in this study (#0.2%) is nearly 100-fold less 
than the values recommended by recent guidelines, which 
consider formulations with hemolysis values of ,10% to 
be nonhemolytic.13
Although a higher pH would be expected to improve 
the stability of epoprostenol, it is likely that the extended 
stability of epoprostenol AM relative to epoprostenol GM 
is not solely due to this effect, but also due to the other 
features of arginine (high buffer capacity) as compared 
with glycine. Arginine is widely used to prevent protein 
degradation in aqueous solution because of its ability to 
suppress protein aggregation, although the exact mecha-
nism by which it achieves this is unclear.19 It is theoretically 
possible that the improved stability of epoprostenol AM 
may be linked to the presence of multiple ionic binding 
sites on the arginine molecule (guanidine amine and sec-
ondary amine) that could potentially form an ionic cluster 
with multiple molecules of epoprostenol and therefore 
create a sterically protective environment and so decrease 
the rate of hydrolysis.
Recommendations for the shelf-life of fully diluted epo-
prostenol AM stored in the medication cassette based on the 
microbiological and stability data obtained in this study are 
shown in Table 8.
Conclusion
Epoprostenol AM has improved thermal stability, allowing 
it to be fully diluted immediately after reconstitution and 
stored ready for use for up to 72 hours at 25ºC, depending on 
concentration, using readily available intravenous diluents. 
This extended stability under ambient conditions has the 
potential to improve convenience for patients, with long-
term administration requiring change of medication cassettes 
every 24 hours for concentrations above 3,000 ng/mL, and 
without the need for ice packs. Fully diluted epoprostenol 
AM is self-preserving, and did not support the growth of 
any microorganism tested for up to 48 hours at room tem-
perature or 14 days when refrigerated. This product has been 
successfully and safely administered to human patients in 
clinical studies20 and has been available commercially for 
more than 2 years.
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Table 8 Recommended shelf-life at 25°C of diluted epoprostenol AM
Concentration range Immediate use after dilutiona After storage for 1 day at 5°C After storage for 7 days at 5°C
$3000–,6000 ng/mL 12 hours Do not use Do not use
$6000–,9000 ng/mL 24 hours 12 hours Do not use
$9000–,12,000 ng/mL 24 hours 12 hours 12 hours
$12,000–,30,000 ng/mL 24 hours 24 hours 12 hours
$30,000 ng/mL 72 hours 48 hours 24 hours
Note: aIn either sterile water for injection or sterile saline (sodium chloride 0.9%) for injection.
Abbreviation: AM, arginine and mannitol.
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